A former representative has filed a complaint with the Philippine Competition Commission urging them to investigate an "anti-competitive" move of a drug manufacturer to block other bidders of the pneumococcal conjugate vaccine (PCV) by decreasing its price.
According to former Abakada partylist representative and current national adviser of the United Filipino Consumers and Commuters (UFCC) Jonathan de la Cruz, Pfizer allegedly decreased its PCV13 price to P315 per dose, which is more than half of the P816 average price when it was first procured by the Department of Health (DoH) in 2014.
Already have an active account? Log in here.
Continue reading with one of these options:
Continue reading with one of these options:
Premium + Digital Edition
Ad-free access
P 80 per month
(billed annually at P 960)
- Unlimited ad-free access to website articles
- Limited offer: Subscribe today and get digital edition access for free (accessible with up to 3 devices)
TRY FREE FOR 14 DAYS
See details
See details
If you have an active account, log in
here
.